Gautam Shah on market bottom and Nifty’s next move

Gautam Shah of Goldilocks Premium Research expresses confidence in select market sectors despite uncertainty in the Nifty’s direction. He highlights opportunities in financial services, metals, power, infrastructure, and real estate, suggesting substantial gains in metal stocks over the next 6 to 12 months.

PhysicsWallah files draft papers for Rs 4,600 crore IPO

Startups, which are eyeing public listing, are increasingly opting for confidential filing route amid choppy and unpredictable markets that have nudged several new age companies to reassess and go slow on their IPO plans.

Stocks to buy: Swiggy, RVNL and TVS Motor on investors’ radar

Sensex surged 1,131 points, revisiting the 75,000 level, and Nifty rose 1.45% on global bullish trends. Paytm gained 8%, with resistance at 770 and support at 710. Cipla is breaking out above 1500, support at 1450. Bajaj Finserv is weak, with downside levels at 1820-1800. Analyst suggestions include cautious trading and adhering to stop losses.

Zydus Lifesciences shares in focus after FDA approval for prostate cancer drug

Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last week’s approval for Eluxadoline tablets for IBS treatment. The stock shows a hold rating with an 18% target price upside. Despite recent approvals, the shares have declined 7% year-to-date.